The estimated Net Worth of Steven Prestrelski is at least $2.3 Millón dollars as of 22 February 2022. Dr Prestrelski owns over 11,228 units of Xeris Biopharma Inc stock worth over $1,661,683 and over the last 6 years he sold XERS stock worth over $641,277.
Dr has made over 8 trades of the Xeris Biopharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 11,228 units of XERS stock worth $7,747 on 22 February 2022.
The largest trade he's ever made was selling 27,700 units of Xeris Biopharma Inc stock on 14 January 2019 worth over $332,677. On average, Dr trades about 5,508 units every 61 days since 2018. As of 22 February 2022 he still owns at least 581,008 units of Xeris Biopharma Inc stock.
You can see the complete history of Dr Prestrelski stock trades at the bottom of the page.
Dr. Steven J. Prestrelski is the Co-Founder & Chief Scientific Officer at Xeris Biopharma Inc.
Dr Prestrelski is 57, he's been the Co-Founder & Chief Scientific Officer of Xeris Biopharma Inc since . There are 9 older and 5 younger executives at Xeris Biopharma Inc. The oldest executive at Xeris Biopharma Holdings Inc is Jeffrey Sherman, 65, who is the Independent Director.
Steven's mailing address filed with the SEC is C/O XERIS BIOPHARMA HOLDINGS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO, IL, 60601.
Over the last 6 years, insiders at Xeris Biopharma Inc have traded over $2,845,230 worth of Xeris Biopharma Inc stock and bought 2,912,235 units worth $31,442,123 . The most active insiders traders include Group, Llc Green Jeremy Red..., James E Deerfield Mgmt L.P.... y Garheng Kong. On average, Xeris Biopharma Inc executives and independent directors trade stock every 46 days with the average trade being worth of $197,048. The most recent stock trade was executed by John P. Schmid on 12 August 2024, trading 4,515 units of XERS stock currently worth $10,159.
xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.
Xeris Biopharma Inc executives and other stock owners filed with the SEC include: